Royalty Financing Partnering Terms and Agreements Discussed in New Cutting-Edge CurrentPartnering Report
08 Jan 2013 • by Natalie Aster
Comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies are provided in the new report “Royalty Financing Partnering Terms and Agreements” by CurrentPartnering.
The report provides a detailed understand and analysis of how and why companies enter royalty financing partnering deals.
Royalty Financing Partnering Terms and Agreements
Published: December, 2012
Price: US$ 2,695.00
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
More information can be found in the report “Royalty Financing Partnering Terms and Agreements” by CurrentPartnering.
To order the report or ask for sample pages contact [email protected]